FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

RegolamentazioneOne-OffHealth & Medicine6m

KalshiVerifica disponibilitàKYC richiesto2% di commissione

Probabilità implicita attuale

Sì 0%

Qualita del mercato

24 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

0 €

Bassa liquidità

Bid / Ask

61.0% / 69.0%

Spread

13.1%

Spread ampio

Dati di mercato

Aggiornato 3 minuti fa

17 giu 26, 21:001 gen 27, 4:59

Trend

Esito24hProbabilità

Sì

100%

Esito scelto

Yes0%

Puntata (USDT)

Regole

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.

Mercati Correlati

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €

Sì: 22.2%

MANIFOLD MARKETS

Will China have more phase 3 drug trials than the United States in year X?

367,9 €

2026: 33%

MANIFOLD MARKETS

Will estradiol be available over-the-counter in the US before 2030?

303 €

Sì: 8.2%

MANIFOLD MARKETS

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

0 €

Sì: 0%

KALSHI

Hantavirus pandemic in 2026?

38,2K €

Sì: 4%

POLYMARKET

New pandemic in 2026?

5,2K €

Sì: 11%

POLYMARKET

Attivi in questi argomenti

BitcoinBTC$64,565.28-1.93%

EthereumETH$1,754.71-2.39%

SolanaSOL$72.38-1.70%

DogecoinDOGE$0.0862-1.45%

XRPXRP$1.19-2.25%

BNBBNB$602.70-0.56%

Notizie Correlate

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain Reporter

CLARITY Act faces ethics showdown as David Nage eyes July voteCrypto News

Binance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain Reporter

Solana Institute warns Senate against weakening CLARITY ActCrypto News

Summer of crypto (regs): State of Crypto Coindesk

Philippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Regole

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

RegolamentazioneOne-OffHealth & Medicine6m

KalshiVerifica disponibilitàKYC richiesto2% di commissione

Probabilità implicita attuale

Sì 0%

Qualita del mercato

24 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

0 €

Bassa liquidità

Bid / Ask

61.0% / 69.0%

Spread

13.1%

Spread ampio

Dati di mercato

Aggiornato 3 minuti fa

17 giu 26, 21:001 gen 27, 4:59

Trend

Esito24hProbabilità

Sì

100%

Esito scelto

Yes0%

Puntata (USDT)

Regole

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.

Mercati Correlati

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €

Sì: 22.2%

MANIFOLD MARKETS

Will China have more phase 3 drug trials than the United States in year X?

367,9 €

2026: 33%

MANIFOLD MARKETS

Will estradiol be available over-the-counter in the US before 2030?

303 €

Sì: 8.2%

MANIFOLD MARKETS

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

0 €

Sì: 0%

KALSHI

Hantavirus pandemic in 2026?

38,2K €

Sì: 4%

POLYMARKET

New pandemic in 2026?

5,2K €

Sì: 11%

POLYMARKET

Attivi in questi argomenti

BitcoinBTC$64,565.28-1.93%

EthereumETH$1,754.71-2.39%

SolanaSOL$72.38-1.70%

DogecoinDOGE$0.0862-1.45%

XRPXRP$1.19-2.25%

BNBBNB$602.70-0.56%

Notizie Correlate

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain Reporter

CLARITY Act faces ethics showdown as David Nage eyes July voteCrypto News

Binance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain Reporter

Solana Institute warns Senate against weakening CLARITY ActCrypto News

Summer of crypto (regs): State of Crypto Coindesk

Philippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Regole

If the FDA's decision on DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
DTX401 (pariglasgene brecaparvovec) is a one-time gene therapy developed by Ultragenyx Pharmaceutical to treat Glycogen Storage Disease Type Ia (GSDIa), a rare inherited disorder in which the liver cannot properly release stored sugar into the bloodstream.
Think of it like installing a corrected instruction manual inside liver cells: after a single infusion, the therapy is designed to restore the missing enzyme activity — glucose-6-phosphatase — so the liver can once again regulate blood sugar on its own.
In the Phase 3 GlucoGene trial , DTX401 produced a statistically significant 41.3% mean reduction in daily cornstarch intake at Week 48 versus 10.3% for placebo (p<0.0001), with durability data at 96 weeks showing approximately 60–61% reductions.